Lymphoma and leukemia in rheumatoid arthritis: Are they associated with azathioprine, cyclophosphamide, or methotrexate? A matched case-control study in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) population

Journal of Clinical Rheumatology

Volumn 2, Issue 2, 1996, Pages 64-72

  Williams, Catherine A ^a,g   Bloch, Daniel A ^b   Sibley, John ^c   Haga, May ^c   Wolfe, Fred ^d   Raynauld, Jean Pierre ^e   Singh, Gurkirpal ^b   Hickey, Anne R ^f   Fries, James F ^b  

^a BRI International

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^e Glaxo Wellcome ^*

^f Glaxo Wellcome

^g BRI International Inc   (United States)

Author keywords

Arthritis; Case control study; Disease modifying antirheumatic drugs; Leukemia; Lymphoma; Rheumatism and Aging Medical Information System (ARAMIS)

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

EID: 0029973336     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199604000-00002     Document Type: Article

References (43)

1. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-696.
2. Urowitz MB, Smythe HA, Able T, Norman CS, Travis C. Long-term effects of azathioprine in rheumatoid arthritis. Ann Rheum Dis 1982;41 (suppl):18-22.
3. Baltus JAM, Boersma JW, Hartman AP, Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983; 42:368-373.
4. Prior P, Symmons DPM, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-131
5. Symmons DPM, Ahern M, Bacon PA, et al. Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. Ann Rheum Dis 1984;43:132-135.
6. Castor CW, Bull FE. Review of United States data on neoplasms in rheumatoid arthritis. Am J Med 1985;78 (suppl 1A):33-38.
7. Hazelman B, De Silva M. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982;41 (suppl):12-17.
8. Tilson HH, Whisnant J. Pharmaco-epidemiology - drugs, arthritis, and neoplasms: industry contribution to the data. Am J Med 1985; 78 (suppl 1A):69-76.
9. Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med 1985;78 (suppl 1A):15-21.
10. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78 (suppl 1A):44-49.
11. Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985;78 (suppl 1A):50-55.
12. Vaughn JH. Immune system in rheumatoid arthritis: possible implications in neoplasms. Am J Med 1985;78 (suppl 1A):6-11.
13. Symmons DPM. Neoplasia in rheumatoid arthritis. J Rheumatol 1988;15:1319-1322.
14. Silman AJ, Petrie J, Hazleman B, Evans SJW. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988;47:988-992.
15. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB, Members of the Rheumatoid Arthritis Azathioprine Registry Steering Committee. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991;18:809-814.
16. Porter D, Madhok R, Cappell H. Non-Hodgkin's lymphoma in rheumatoid arthritis. Ann Rheumatic Dis 1991;50:275-276.
17. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992;3:449-456.
18. Gridley G, McLaughlin JK, Edbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85(4): 307-311.
19. Wilson S, Brooks PM. Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 1993; 5:99-103.
20. Laakso M, Mutru O, Isomaki H, Koota K. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986;13:522-526.
21. Donnelly S, Amos R, Norton J, Rohatiner AZS, Scott DL, DMP Symmons. Grand rounds in rheumatology: a patient with rheumatoid arthritis and lymphoma. Br J Rheumatol 1992; 31:107-112.
22. Kamel OW, Van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994;25: 638-643.
23. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37(4):481-194.
24. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991;18:1172-1175.
25. Ellman MH, Hurwitz, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991;18:1741-1743.
26. Cobeta-Garcia JC, Ruiz-Himeno MT, Fontova-Garrofe R. Non-Hodgkin's lymphoma, rheumatoid arthritis and methotrexate. J Rheumatol 1993;20:200-201.
27. Morris CR. Localized lymphoma in a patient with rheumatoid arthritis treated with parenteral methotrexate. J Rheumatol 1993;20:2172-2173.
28. Taillan B, Garnier G, Castanet J, Ferrari E, Pesce A, Dujardin P. Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate. Clin Rheumatol 1993;12:93-94.
29. Zimmer-Galler I, Lie JT. Choroidal infiltrates as the initial manifestation of lymphoma in rheumatoid arthritis after treatment with low-dose methotrexate. Mayo Clin Proc 1994;69: 258-261.
30. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992;19:1462-1465.
31. Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 1959;2: 16-20.
32. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
33. Kelsey JL, Thompson WD, Evans AS. Methods in observational epidemiology. New York: Oxford University Press, 1986:178-182.
34. Layard MW. Medlog. A micro-computer based clinical data management system. Proceedings of the Congress on Medical Informatics. Bethesda, Maryland: AAMSI Publishers, 1983;1:454-468.
35. McCarty DJ. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J Rheumatol 1990;17:1115-1118.
36. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:365-567.
37. Fries JF. Safety issues related to DMARD therapy. J Rheumatol 1990;25 (suppl.):14-17.
38. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36: 297-306.
39. Fries JF, Williams CA, Morfeld D, Singh G, Wolfe F, Sibley J. Reduction in longterm disability in rheumatoid arthritis (RA) by DMARD-based treatment strategies. Arthritis Rheum 1996;39:in press.
40. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1449-1461.
41. Tennis P, Andrews E, Bombardier C, et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada. J Clin Epidemiol 1993;46(7): 685-695.
42. Schlesselman JJ. Case-control studies. New York: Oxford University Press, 1982.
43. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley and Sons, 1981, p. 114.